Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.

ABSTRACT:

Background

Little is known about targeted (antiviral or monoclonal antibody) anti-SARS-CoV-2 treatment in immunocompromised patients with COVID-19.

Objectives

To assess the real-life efficacy and tolerance of targeted treatment of COVID-19 in immunocompromised patients.

Patients and methods

Single-centre retrospective case series of immunocompromised patients with COVID-19 between December 2021 and March 2022. We recorded all cases of COVID-19 among immunocompromised patients treatment between 20 December 2021 and 15 March 2022. Choice of treatment was left to the physician's decision, according to internal treatment protocol, treatment availability and circulating variants. Main outcome was death from COVID-19 after no treatment or targeted treatment.

Results

SUBMITTER: Lafont E 

PROVIDER: S-EPMC9384481 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature